Theravance Biopharma (NASDAQ: TBPH) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Theravance Biopharma to similar companies based on the strength of its dividends, institutional ownership, risk, profitability, analyst recommendations, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Theravance Biopharma and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theravance Biopharma 0 0 5 0 3.00
Theravance Biopharma Competitors 838 3762 6791 185 2.55

Theravance Biopharma currently has a consensus target price of $46.80, indicating a potential upside of 59.24%. As a group, “Pharmaceuticals” companies have a potential upside of 27.56%. Given Theravance Biopharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Theravance Biopharma is more favorable than its peers.


This table compares Theravance Biopharma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Theravance Biopharma -742.59% -78.74% -43.79%
Theravance Biopharma Competitors -2,859.74% -67.95% -9.23%

Risk & Volatility

Theravance Biopharma has a beta of 2.24, suggesting that its share price is 124% more volatile than the S&P 500. Comparatively, Theravance Biopharma’s peers have a beta of 0.89, suggesting that their average share price is 11% less volatile than the S&P 500.

Earnings and Valuation

This table compares Theravance Biopharma and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Theravance Biopharma $31.36 million -$211.25 million -6.35
Theravance Biopharma Competitors $8.20 billion $2.68 billion -1.27

Theravance Biopharma’s peers have higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

84.9% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.1% of Theravance Biopharma shares are owned by company insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with's FREE daily email newsletter.